3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Nivolumab
2
Cyclophosphamide
2
tislelizumab
1
spartalizumab
1
pembrolizumab
1
montanide ISA 51
1
glembatumumab vedotin
1
fludarabine phosphate
1
entinostat
1
cemiplimab
1
Toll-Like Receptor 1
1
Surveys and Questionnaires
1
Specimen Handling
1
Rose Bengal
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-2
1
Interleukin-13
1
Focus Groups
1
Fluorodeoxyglucose F18
1
Cryosurgery
1
CTLA-4 Antigen
1
CR011-vcMMAE
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Toll-Like Receptor 1
×
Breast
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled